FDA Approves Eli Lilly's Jardiance For Heart Failure

by Vandana Singh, Benzinga Editor

August 18, 2021 2:08 PM | 1 min read |

The FDA approves Eli Lilly And Co LLY - Boehringer Ingelheim's Jardiance (empagliflozin) 10 mg for heart failure.
The approval comes to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).
Jardiance can be initiated in adults with HFrEF with an eGFR as low as 20 mL/min/1.73 m2.
The approval is based on results from the EMPEROR-Reduced Phase 3 trial.
In the trial, Jardiance significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25% (5.3% absolute risk reduction) versus placebo.
Related content: Benzinga's Full FDA Calendar.
Price Action: LLY shares are down 0.02% at $272.65 during the market session on the last check Wednesday.

Posted In:

Biotech News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.